Furthermore, for CYP2C subfamily members, CYP2C8, CYP2C9, and CYP2C19 were reported to be potential serum biomarkers for the early diagnosis of HCC, and high expression levels of them were associated with a reduced risk of death [27]. This evidence concerns the gene CYP2C8 and hepatocellular carcinoma.